167 related articles for article (PubMed ID: 26463269)
1. Emergence of Photosensitivity with Decreased Treg Cells in a Patient with Mycosis Fungoides Treated with Anti-CC Chemokine Receptor 4 Antibody Mogamulizumab.
Tatsuno K; Sano T; Fukuchi K; Kuriyama S; Aoshima M; Kasuya A; Ikeya S; Fujiyama T; Ito T; Tokura Y
Acta Derm Venereol; 2016 Mar; 96(3):420-1. PubMed ID: 26463269
[No Abstract] [Full Text] [Related]
2. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
3. Mogamulizumab-induced photosensitivity in patients with mycosis fungoides and other T-cell neoplasms.
Masuda Y; Tatsuno K; Kitano S; Miyazawa H; Ishibe J; Aoshima M; Shimauchi T; Fujiyama T; Ito T; Tokura Y
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1456-1460. PubMed ID: 29341283
[TBL] [Abstract][Full Text] [Related]
4. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
[No Abstract] [Full Text] [Related]
5. Cutaneous adverse reaction of mogamulizumab, an anti-CC chemokine receptor 4 monoclonal antibody: Shared histopathological features with thymoma-associated multi-organ autoimmunity.
Kanno K; Honma M; Ishida-Yamamoto A
J Dermatol; 2017 Jun; 44(6):e117-e118. PubMed ID: 28026038
[No Abstract] [Full Text] [Related]
6. Bath-PUVA therapy decreases infiltrating CCR4-expressing tumor cells and regulatory T cells in patients with mycosis Fungoides.
Kato H; Saito C; Ito E; Furuhashi T; Nishida E; Ishida T; Ueda R; Inagaki H; Morita A
Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):273-80. PubMed ID: 23332394
[TBL] [Abstract][Full Text] [Related]
7. Association of autoimmunity and long-term complete remission in patients with Sézary syndrome treated with mogamulizumab.
Bonnet P; Battistella M; Roelens M; Ram-Wolff C; Herms F; Frumholtz L; Bouaziz JD; Brice P; Moins-Teisserenc H; Bagot M; de Masson A
Br J Dermatol; 2019 Feb; 180(2):419-420. PubMed ID: 30328116
[No Abstract] [Full Text] [Related]
8. FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome.
Kasamon YL; Chen H; de Claro RA; Nie L; Ye J; Blumenthal GM; Farrell AT; Pazdur R
Clin Cancer Res; 2019 Dec; 25(24):7275-7280. PubMed ID: 31366601
[TBL] [Abstract][Full Text] [Related]
9. CD8+ CD56+ mycosis fungoides with an indolent clinical behaviour: case report and literature review.
Sawada Y; Sugita K; Kabashima R; Hino R; Nakamura M; Koga C; Tokura Y
Acta Derm Venereol; 2010 Sep; 90(5):525-6. PubMed ID: 20814634
[No Abstract] [Full Text] [Related]
10. Clinical Application of Anti-CCR4 Monoclonal Antibody.
Ueda R
Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
[TBL] [Abstract][Full Text] [Related]
11. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.
Kanazawa T; Hiramatsu Y; Iwata S; Siddiquey M; Sato Y; Suzuki M; Ito Y; Goshima F; Murata T; Kimura H
Clin Cancer Res; 2014 Oct; 20(19):5075-84. PubMed ID: 25117294
[TBL] [Abstract][Full Text] [Related]
12. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.
Duvic M; Pinter-Brown LC; Foss FM; Sokol L; Jorgensen JL; Challagundla P; Dwyer KM; Zhang X; Kurman MR; Ballerini R; Liu L; Kim YH
Blood; 2015 Mar; 125(12):1883-9. PubMed ID: 25605368
[TBL] [Abstract][Full Text] [Related]
13. CXCR3 and CCR4 double positive tumor cells in granulomatous mycosis fungoides.
Shimauchi T; Kabashima K; Tokura Y
J Am Acad Dermatol; 2006 Jun; 54(6):1109-11. PubMed ID: 16713487
[No Abstract] [Full Text] [Related]
14. Differential expression of CCR4 in primary cutaneous gamma/delta (γ⁄δ) T cell lymphomas and mycosis fungoides: Significance for diagnosis and therapy.
Jour G; Aung PP; Merrill ED; Curry JL; Tetzlaff MT; Nagarajan P; Ivan D; Prieto VG; Duvic M; Miranda RN; Torres-Cabala CA
J Dermatol Sci; 2018 Jan; 89(1):88-91. PubMed ID: 29030090
[No Abstract] [Full Text] [Related]
15. The treatment of mycosis fungoides.
Mestel DS; Beyer M; Steinhoff M; Sterry W; Assaf C
G Ital Dermatol Venereol; 2008 Dec; 143(6):395-408. PubMed ID: 19169212
[TBL] [Abstract][Full Text] [Related]
16. Poikilodermatous mycosis fungoides.
Farley-Loftus R; Mandal R; Latkowski JA
Dermatol Online J; 2010 Nov; 16(11):8. PubMed ID: 21163159
[TBL] [Abstract][Full Text] [Related]
17. Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome.
Dai J; Almazan TH; Hong EK; Khodadoust MS; Arai S; Weng WK; Kim YH
JAMA Dermatol; 2018 Jun; 154(6):728-730. PubMed ID: 29800117
[TBL] [Abstract][Full Text] [Related]
18. Molluscum contagiosum with CD30+ cell infiltration in a patient with mycosis fungoides.
Ohata C; Fukuda S; Hashikawa K; Ishii N; Hamada T; Nakama T; Furumura M; Tsuruta D; Ohshima K; Hashimoto T
Am J Dermatopathol; 2014 Aug; 36(8):685-7. PubMed ID: 24423931
[No Abstract] [Full Text] [Related]
19. Serum CCL22 levels decreased in parallel with disease activity in CCR4-positive mycosis fungoides treated with mogamulizumab.
Ohuchi K; Fujimura T; Lyu C; Amagai R; Muto Y; Aiba S
Dermatol Ther; 2020 Nov; 33(6):e14099. PubMed ID: 32725764
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
Tawa M; Kopp E; McCann S; Cantrell W
Clin J Oncol Nurs; 2019 Aug; 23(4):E73-E80. PubMed ID: 31322628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
